Royal Bank Of Canada Inovio Pharmaceuticals, Inc. Transaction History

Royal Bank Of Canada

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$0.35 - $0.53 $1,342 - $2,033	-3,837 Reduced 4.93%	73,923 $37,000
Q3 2023 Nov 14, 2023	BUY	$0.38 - $0.58 $24,007 - $36,642	63,177 Added 433.22%	77,760 $30,000
Q2 2023 Aug 14, 2023	SELL	$0.39 - $0.94 $5,382 - $12,972	-13,801 Reduced 48.62%	14,583 $6,000
Q1 2023 May 15, 2023	SELL	$0.79 - $1.91 $266,108 - $643,375	-336,846 Reduced 92.23%	28,384 $23,000
Q4 2022 Feb 14, 2023	BUY	$1.41 - $2.5 $433,707 - $768,985	307,594 Added 533.68%	365,230 $569,000
Q3 2022 Nov 14, 2022	BUY	$1.66 - $2.79 $42,178 - $70,891	25,409 Added 78.84%	57,636 $99,000
Q2 2022 Aug 15, 2022	SELL	$1.44 - $3.98 $18,885 - $52,197	-13,115 Reduced 28.92%	32,227 $55,000
Q1 2022 May 16, 2022	SELL	$2.97 - $5.2 $311,475 - $545,344	-104,874 Reduced 69.82%	45,342 $163,000
Q4 2021 Feb 14, 2022	BUY	$4.99 - $7.46 $398,047 - $595,076	79,769 Added 113.23%	150,216 $750,000
Q3 2021 Nov 15, 2021	BUY	$7.16 - $9.69 $133,877 - $181,183	18,698 Added 36.13%	70,447 $504,000
Q2 2021 Aug 16, 2021	BUY	$6.23 - $10.03 $322,396 - $519,042	51,749 New	51,749 $480,000

281K

Ticker INO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 249,400,000
Market Cap $456M
Description
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA se...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.